Author:
Klenner T.,Wingen F.,Keppler B.,Valenzuela-Paz P.,Amelung F.,Schmähl D.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference35 articles.
1. Adami, S.,Salvagno, G.,Guarrera, G.,Montesanti, F.,Garavelli, S.,Rosini, S., andLocascio, V., 1986, Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.Calcified Tissue International, 39, 226–229.
2. Albanese, R., andWatkins, P. A., 1985, The mutagenic activity of razoxane (ICRF 159): an anticancer agent.British Journal of Cancer,52 (5), 725–731.
3. Attardo-Parrinello, G.,Merlini, G.,Pavesi, F.,Crema, F.,Fiorentini, M. L., andAscari, E., 1987, Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis.Archives of International Medicine,147, 1629–1633.
4. Boonekamp, P.,Van Der Wee-Pals, L. J. A.,Van Wijk-Van Lennep, M. M. L.,Wil Thesing, C., andBijvoet, O. L. M., 1986, Two modes of action of bisphophosphonates on osteoclastic resorption of mineralized matrix.Bone and Mineral,1, 27–39.
5. Canfield, R. E., 1987, Rationale for disphosphonate therapy in hypercalcemia of malignancy.American Journal of Medicine,82 (2A), 1–5.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献